CD73 Immune Checkpoint Defines Regulatory NK Cells Within the Tumor Microenvironment
The Journal of Clinical Investigation RESEARCH ARTICLE CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment Shi Yong Neo,1 Ying Yang,1,2 Julien Record,3 Ran Ma,1 Xinsong Chen,1 Ziqing Chen,1 Nicholas P. Tobin,1 Emily Blake,4 Christina Seitz,5 Ron Thomas,4 Arnika Kathleen Wagner,6 John Andersson,5 Jana de Boniface,7,8 Jonas Bergh,1 Shannon Murray,9 Evren Alici,6 Richard Childs,10 Martin Johansson,11 Lisa S. Westerberg,4 Felix Haglund,1 Johan Hartman,1,12 and Andreas Lundqvist1 1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. 2Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 3Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden. 4Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, Florida, USA. 5Department of Medical Epidemiology and Biostatistics, 6Department of Medicine Huddinge, and 7Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 8Department of Surgery, Capio St. Goran’s Hospital, Stockholm, Sweden. 9Fred Hutchinson Cancer Research Center, Division of Basic Sciences, Seattle, Washington, USA. 10Laboratory of Transplantation Immunotherapy, Hematology Branch, National Heart Lung and Blood Institute, NIH, Bethesda, Maryland, USA. 11Glactone Pharma Development AB, Helsingborg, Sweden. 12Department of Pathology, Karolinska University Laboratory, Södersjukhuset, Stockholm, Sweden. High levels of ecto-5′-nucleotidase (CD73) have been implicated in immune suppression and tumor progression, and have also been observed in cancer patients who progress on anti–PD-1 immunotherapy. Although regulatory T cells can express CD73 and inhibit T cell responses via the production of adenosine, less is known about CD73 expression in other immune cell populations.
[Show full text]